The clinical team at the RVC analysed anonymised clinical data from dogs from the UK, Europe and the USA undergoing mitral valve repair at the Queen Mother Hospital for Animals at the RVC.
One study evaluated the anaesthetic management and outcomes of 176 dogs undergoing surgery, focusing on complications during and around the time of anaesthesia1.
The second study assessed 66 dogs to identify features on heart scans that could help predict whether the heart would remain enlarged after surgery2.
The findings showed that mitral valve repair is associated with significant intraoperative and postoperative risks.
Longer cardiopulmonary bypass duration was associated with increased risk.
Dogs with greater pre-surgical heart enlargement and higher body weight were more likely to have persistent left heart enlargement after surgery.
Close perioperative monitoring and rapid-response protocols were found to be essential in managing anticipated complications.
The study also found that recovery outcomes vary, meaning individual patient factors must be considered when advising owners.
Finally, the research demonstrated that most beneficial changes in heart size, known as reverse remodelling, occurred within the first three months after surgery.
Professor Dan Brockman, Professor in Small Animal Surgery and Director of the Cardiothoracic Surgery Service at the RVC, said: "Establishing and maintaining open heart surgical capability at the RVC has been both the most challenging and the most rewarding activity of my 36 years as a specialist small animal surgeon.
"Our team are rightly proud of what we have achieved, but we all know that the route to even greater consistency of results lies in the constant process of reflection, refinement and improvement in every aspect of what we do."
The RVC is currently the only centre in the UK offering this specialist surgical procedure.
https://www.rvc.ac.uk/small-animal-vet/specialist-referrals/advanced-techniques/cardiothoracic-surgery/mitral-valve-disease
References
The procedure, called transcatheter edge-to-edge repair (TEER), is a minimally invasive alternative to open heart surgery.
TEER is performed on a beating heart using a specially designed “V-Clamp” device which brings the mitral valve leaflets together, reducing the severity of mitral regurgitation.
The procedure is guided by real-time 3D echocardiography and performed via a small thoracotomy, typically 6–8 cm in length.
CVS, which owns Bristol Vet Specialists, says dogs undergoing TEER generally experience a rapid recovery, with most discharged within 48 hours and minimal need for intensive care.
The company says that once heart failure is diagnosed, the average survival time is between nine and 12 months, but that after TEER surgery, 95% of dogs are discharged successfully, and 85% survive for two years post surgery.
The procedure costs £12,000.
http://www.bristolvetspecialists.co.uk
The collection, which is free to read until 7th January 2026, explores:
Laura Nath said: “This collection highlights important and exciting work and improves our understanding of arrhythmogenic mechanisms, diagnosis of arrhythmias and recognition of cardiac pathology in both clinical and research settings.”
https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.current-progress-in-equine-cardiology
The 4D heart model, which can be viewed at: https://static.imascono.com/heartViewer, was designed in conjunction with Alejandro Suarez Bonnet, senior lecturer in comparative pathology at the RVC and consultant pathologist at The Francis Crick Institute.
The model demonstrates the structural changes in the mitral valve and associated heart chambers across stages A to D — from dogs at risk (stage A), through preclinical disease (stages B1 & B2), to symptomatic heart failure (stages C & D).
It has been designed to help pet owners understand the condition’s progression and support clearer communication of monitoring and treatment options.
Callum Watkins, brand manager at Dechra, said: “MMVD often catches dog owners unawares due to the silent early signs and the slow progressive nature of the condition.
“Our new 4D heart model will enable vets to clearly demonstrate the different stages of the disease, including the structural changes in the mitral valve and associated heart chambers, to aid discussions on the monitoring and treatment options.”
https://www.dechra.co.uk/companion-animal/internal-medicine/cardiovascular-disease.
The company says the two main benefits of the liquid formulation are precise dosing and ease of administration.
Vetmedin oral solution comes with a kg-bodyweight calibrated syringe to make it easy to give the preferred dose of 0.25 mg/kg twice daily to the nearest 0.5 kg bodyweight.
The maximum syringe volume is for a 12 kg dog.
The solution has a sweet taste to make it palatable and Boehringer says it is also ideal for dogs that need dental work but require treatment for their heart disease before general anaesthesia.
These dogs might struggle to eat chewable tablets due to oral discomfort, so a liquid treatment might be a better option.
The company highlights the EPIC1 and PROTECT2 studies which showed that Vetmedin delays the onset of CHF for dogs in the asymptomatic stage of heart disease and improves both the quality and length of life for dogs with MVD and DCM.
Vetmedin oral solution comes as a 50 ml bottle (each bottle lasts a 5 kg dog approximately 30 days), doesn't need to be refrigerated, has an 8-week shelf life once opened, and a 2-year shelf life as packaged.
VetMedin oral solution is now available to order from wholesalers.
The project looked first at how effective CVS small animal first opinion practices were at conducting echocardiography.
It found that a barrier to wider uptake was a lack of up-to-date equipment, along with a lack of current knowledge and training - both in using ultrasound and echocardiography equipment and in interpreting images.
CVS says that as a result, many colleagues were routinely referring suspected cardiac disease cases.
The project leaders then reviewed and recommended practice equipment, so that clinicians had the tools to perform echocardiograms in practice.
This included buying echocardiography tables - so that practitioners could scan an animal’s chest from underneath, more advanced cardiac ultrasound machines and electrocardiogram (ECG) machines.
The company then produced a range of resources for vets and nurses, to help them to improve echocardiography scan rates and nurse cardiology clinics, including clinical guidelines, machine guides and client resources.
It then held a number of training sessions for its vets and nurses, focusing on the latest advancements in heart disease diagnosis and treatment for vets, and training nurses how to conduct nurse cardiology clinics, how to perform and interpret electrocardiography, how to take blood pressure readings and thoracic point of care ultrasound (POCUS).
Lynsay Morgan, Regional Clinical Lead at CVS who is responsible for the cardiac ultrasound clinical improvement project, said: “We want to empower our first opinion small animal vets to perform more echo evaluations and to work up their cardiology cases to a high standard.
"We also want our nurses to be involved in patients’ life-long care, and provide ongoing support to owners of pets with heart disease.
“We hope this project will improve case identification, increase skills and confidence, and see optimum diagnosis and management of cardiac disease.”
The pair were invited to carry out the laparoscopic surgery on four dogs suffering from pulmonic stenosis by the British Veterinary Centre.
Chris Linney said: “The British Veterinary Clinic had previously referred a case to Fabio at Willows and subsequently got in touch about a further four cases in need of surgery, inviting us to fly out to Abu Dhabi to operate on these cases for them.
“It was a pioneering moment for the British Veterinary Centre and a first for the region and the Middle East.
“It’s the very first time that interventional cardiology has been performed in the UAE so, with the fantastic facilities and dedicated staff at the BVC, we have made history in the region!
“It was also the first time that Fabio and I had worked together and now we hope that this will be the first of many such collaborations.”
Fabio added: “With our collective expertise and knowledge, we know we can improve the lives of so many dogs that are living with conditions like pulmonic stenosis.
“Two of the dogs required balloon valvuloplasty and two required pulmonary stents inserted.
“All four dogs had great initial post-operative results and would be expected to lead happier, healthier lives as a result of these procedures.'
The webinar will cover the entire disease process of MMVD in dogs from pathology to current treatment approaches and future advancements in therapy, and will include the following presentations:
https://us06web.zoom.us/webinar/register/WN_QyfUofLgRG-YsaXQbkT7Tw#/registration
The new formula also contains crataegus, L-carnitine and magnesium taurate, and is designed to be used alongside all heart medications.
Alongside the launch of the new product, Vita has also created an infographic highlighting the common signs of heart disease in dogs.
https://vitaanimalhealth.com/common-signs-of-heart-disease
https://vitaanimalhealth.com/product/omnicardio-plus
Andrew, who graduated in 2002 from The University of Bristol, started as a farm vet in Devon and Cornwall, which is where he first became interested in cardiology.
He went on to undergo Specialist Training at The University of Edinburgh and then spent four years working in the pharmaceutical industry.
Andrew then spent almost two years as Head of Cardiology at a large referral hospital in Winchester, before leaving to co-found the first ever video consulting platform for pet owners, Pawsquad.
Since then, he has led teams in some of the largest specialist veterinary referral hospitals in Europe.
More recently, Andrew has run his own specialist-led visiting cardiology service, providing clinical consultancy services to 50 veterinary practices across the south of England for the last five years.
Andrew has been an EBVS European Veterinary Specialist in Small Animal Cardiology and a RCVS Recognised Specialist in Veterinary Cardiology for 10 years.
At Lumbry Park, Andrew plans to use his new role to provide specialist-led care to pets from across the South of England, and to provide cardiac clinical input for the multi-disciplinary team at Lumbry Park who manage patients with some of the most complex clinical problems in the country.
www.lumbrypark.co.uk
The company’s NEMO Cardiac Health Screening test detects heart disease using AI to analyse microRNAs - biomarkers that manage the immune system and its responses and act as regulators for disease progression or resolution.
MI:RNA says the new test, which can be taken from blood or urine samples, will help vets diagnose and monitor disease progression more effectively and give cats and dogs with heart disease 18 months more life.
Eve Hanks, CEO and founder of MI:RNA (pictured) said: “The use of precision medicine in veterinary diagnostics will help pet owners and breeders alike to ascertain where to direct their efforts and finances accordingly.
"There is massive potential to use this technology to help breeds who have real problems with heart and other diseases, and will consequently help owners and breeders to identify affected animals more quickly.
Professor Joanna Dukes-McEwan, Head of the Cardiology Service at the University of Liverpool said: "From our cardiac investigations, we knew exactly the underlying heart disease and the severity of this, so our data was used as a training set for the MI:RNA panel analysis.
"We have previously collected samples from dogs with myxomatous mitral valve disease and are currently collecting samples from cats with hypertrophic cardiomyopathy.
“I think the MI:RNA panels are most useful for vets in primary care practice to identify and confirm the severity of underlying cardiac disease in their patients.
"A simple blood test which could confirm that the cause of a heart murmur is MVD, and also indicate its severity, and whether the patient would benefit from treatment would be really helpful for primary care vets in practice.
"They might indicate which patients may benefit from referral, or indicate when a specific treatment is indicated.
"Future research with miRNA panels may also indicate novel pathways in progression of disease which might increase our understanding of the disease, or novel therapeutic options.”
The first two episodes, which discuss feline cardiomyopathy, are available now at: https://www.buzzsprout.com/2189360 and all the leading podcast platforms (including Apple, Spotify, Amazon and Google).
Future topics will include pre-clinical feline cardiomyopathy and a practical approach to puppy murmurs.
There'll also be a number of special guests, including Prof Virginia Luis Fuentes from the Royal Veterinary College, who will discuss the treatment of feline heart disease beyond standard therapy, and Dr Brian Scansen from Colorado State University, who will talk you through the diagnosis and management of pulmonic stenosis.
To keep up with the latest from Kieran and Jose, you can follow them on Twitter or Instagram @heartbeat_pod.
They'd also love you to post to questions for their guests, or any comments you have about the podcasts, on their social media channels.
The procedure involves introducing a catheter through the jugular, then using fluoroscopy and transoesophageal echocardiography to guide it from the right atrium through to the left side of the heart to relieve abnormal high pressures in the left atrium.
Willows says it is one of only a few centres across Europe equipped to carry out the procedure and that typically, patients who undergo TSP can be discharged from hospital the day after surgery.
Fabio Sarcinella (pictured right), an RCVS and European specialist in small animal cardiology at Willows, said: “Early clinical evaluation of the TSP procedure in humans over the last few years has shown improved quality of life and reduced clinical signs in patients with heart failure.
“The procedure has also been associated with low-risk and a meaningful drop in left atrial pressure of the affected patients.”
Fabio added: “As well as being minimally invasive, the improvement in heart chamber pressures via TSP often allows for a reduction in the dose of water tablets which are used to control the heart failure signs in the lungs.
"Lowering the dose reduces the risk of side effects related to these drugs such as kidney failure.”
Willows says TSP is most commonly used for left atrial decompression in dogs with heart failure and concurrent renal disease or that have advanced heart failure but continue to have symptoms despite optimal medical treatment.
www.willows.uk.net
The survey of 1,019 dog owners was conducted by petbuzz in December 2022.
Veterinary cardiology specialist, Dr Rachel James, said: “The CKCS has long been a very popular breed of dog in high demand, due to their loving and placid nature making them perfect family pet.
"We know that sadly at least 50% of CKCS have evidence of MVD disease by the time they are five, with 98% of dogs affected in their lifetimes.
"However, we can help our clients when selecting this breed to choose a puppy that is less likely to develop MVD at an early age, by utilising the heart testing scheme (Doppler heart testing).
"Prospective owners should be asking to see test results for the parents, grandparents, and even better great grandparents too, on both maternal and paternal sides.
"In addition breeders need more support and education to encourage the use of the heart testing scheme and how this can enable them to choose the best dogs to breed from.
"Furthermore we should be encouraging breeders to breed from dogs only when they are at least 3 years of age.”
Vita Animal Health commissioned the survey to raise awareness of the condition and to remind owners to use their vet’s expertise.
Vita’s veterinary nurse, Tara Evans, said: “The CKCS is a very popular breed of dog, perhaps set to be more so now King Charles III is reigning monarch.
"This survey has shown that awareness of mitral valve disease – which is very common in this breed – is not as good as it could be.
"We want to support vets in raising awareness and have useful resources such as our heart disease infographic (www.vitaanimalhealth.com/common-signs-of-heart-disease) that we welcome all vets in using.”
Willows says it is currently the only centre in the UK to offer the procedure, and one of very few in the world.
Simon Swift, an RCVS and European specialist in small animal cardiology (pictured right), heads the cardiology team at Willows.
He said: “Transcatheter edge-to-edge mitral valve repair (TEER) is already considered an alternative to surgical repair in human patients and there have been some very promising early clinical results in dogs.
“The procedure is performed under general anaesthesia through a small incision in the chest wall.
“Access within the beating heart is achieved by a needle puncture at the apex of the heart which is highlighted by continuous X-ray images and an ultrasound of the heart via a probe placed in the oesophagus.
“This allows correct positioning of a V-clamp across the mitral valve to reduce the amount of leakage.
“It’s a procedure that delivers meaningful results and an improved quality of life and, because it’s a minimally invasive process, patients are typically discharged from hospital within two days.”
The audit1 was led by Paragon Veterinary Referrals’ head of cardiology, Chris Linney (pictured), to review treatment for patent ductus arteriosus.
He set up the study whilst working at Willows Veterinary Centre and Referral Service, and the other centres collaborating on the study were Anicura Oslo Animal Hospital, Heart Vets; Royal (Dick) School of Veterinary Studies and the Roslin Institute, University of Edinburgh, University Hospital of Companion Animals, Copenhagen and Veterinary Cardiology Consultancy.
Other clinicians taking part included Brigite Pedro, Mike Martin and João Neves, formerly of Willows, along with Jo Harris and Dave Dickson, of HeartVets.
Chris, an RCVS and EBVS specialist in cardiology, said: “This published multicentre prospective clinical audit was a first of its kind in the cardiology world.
“This type of audit acts as a quality control to improve patient outcomes through systematic review of care, comparing to predefined criteria and then implementing change, and so the process repeats.
“Improving patient outcomes and benchmarking against existing standards is essential for elevating patient outcomes.
In the centres in this study, we are already delivering excellent patient outcomes but with room for improvements, however small, this audit will help future patients but also colleagues across the cardiology world.”
Reference
Mike, an RCVS Queen’s Medal winner, will be in conversation with Catheryn Partington BVSc CertAVP(VC) MSc MRCVS, Jose Matos DVM DipECVIM (Cardiology) MRCVS European and RCVS Recognised Specialist in Small Animal Cardiology (canine and feline cardiology) and Paul Freeman MA, VetMB, Cert SAO, Dip ECVN, MRCVS (European and RCVS Specialist in Veterinary Neurology) (canine and feline neurology).
During the event, they will be explaining how Improve's new Academy Series can help vet professionals meet their annual CPD targets, learn through self-assessment and reflective study, and bring them to the forefront of medicine in several specialist areas.
Heber Alves, CEO of Improve International, said: “Here at Improve International, we are proud to be providing CPD training alongside the historic and prestigious University of Cambridge for our first Academy Series.
"We are excited to be working with many of its pioneering specialists at the Department of Veterinary Medicine and, as a former vet myself, I look forward to hearing how my fellow veterinarians handled the most difficult challenges of their careers.”
www.improveinternational.com
Dave Dickson MRCVS (pictured right) said: "The ECG series is full of case examples and practical advice, delivered by the friendly cardiologists at HeartVets.
"The course should give you confidence to record and interpret ECGs in practice, knowing how to put the ECG information into context with each case and improving how you manage cardiac cases in practice."
ECGs for Vets and Nurses, an online course offering an introduction to ECGs.
The course, which costs £95 for three month's access, has over seven-and-a-half hours of content, divided up into 20-45 minute webinars, so you can watch at your own pace.
For more information, visit: https://heartvets.co.uk/learning-zone/
For this study, researchers in Argentina, Italy, Austria and Chile, set out to evaluate the efficacy of and adverse events from the administration of ACEIs to treat preclinical MMVD in dogs, via a systematic review of published evidence conducted according to the Cochrane Handbook for Systematic Reviews of Interventions.
Certainty of evidence was assessed using the GRADE (https://gradepro.org) approach.
The main finding in relation to dogs with preclinical MMVD and cardiomegaly was backed by a high certainty of evidence. The certainty of evidence in relation to the efficacy of ACEI administration in dogs without cardiomegaly was low.
Dr Pablo Donati, corresponding author for the paper, said: “In recent times, multiple clinical trials have provided fundamental information to veterinary cardiology.
"In the era of evidence-based medicine, systematic reviews and meta-analyses have emerged as a fundamental tool for clinical decision-making by gathering, appraising and summarizing the best available evidence.
"It is the hope of the authors that this systematic review and meta-analysis helps in the decision-making process for the treatment of preclinical myxomatous mitral disease with angiotensin-converting enzyme inhibitors in dogs.”
Nicola Di Girolamo, Editor of JSAP, added: “In line with other leading journals, the JSAP is prioritizing the publication of methodologically sound systematic reviews such as this one.
"However, our readers should be aware that the findings of systematic reviews should always be considered in light of their internal validity, i.e. the quality of the included studies, and their external validity, i.e. the generalizability of the included studied to the individual patient.”
Donati, P., Tarducci, A., Zanatta, R., Verdier, N., Belerenian, G., Cordero, I., Villalta, C., Franco, J. and Tarragona, L. (2022), Angiotensin-converting enzyme inhibitors in preclinical myxomatous mitral valve disease in dogs: systematic review and meta-analysis. J Small Anim Pract. https://doi.org/10.1111/jsap.13461
Anne is originally from New York City and obtained her veterinary degree from Purdue University in 2011.
She completed her rotating internship at Louisiana State University, followed by two research fellowships at Michigan State University and Nihon University.
She then completed her residency at the RVC, before achieving diplomate status of the American College of Veterinary Internal Medicine (Cardiology) in 2017.
Anne's interests include treatment and management of congestive heart failure, feline cardiomyopathy and cardiac interventions.
She said: “I’m delighted to be joining the cardiology team at DWR at a very exciting time, supporting the recently-launched open-heart surgery service.
“We’re one of very few hospitals in the world to be able to offer this treatment, so being a part of this is a great challenge, both personally and professionally.”
For more information visit www.dickwhitereferrals.com
The referral centre has invested in a new heart and lung machine, and an oxygen cage, and is expected to take its first patients in the autumn.
The service will be established and led by head of cardiac surgery Poppy Bristow (pictured right) and head of cardiology Anne Kurosawa, who have already performed this kind of surgery on more than 100 dogs to date.
DWR is also setting up its own blood transfusion service to collect blood from staff and clients’ pets to support the service.
The blood collected will also be used to support the practice’s emergency and critical care service and its planned dialysis programme.
Poppy said: “There are hardly any other centres in the world offering this type of surgery, especially with this level of expertise that comes from the collective team we have gathered at DWR.
“Mitral valve disease is the most common heart condition in dogs and sadly, many dogs die every year as there are very few options for treatment. To be able to offer surgery to more dogs and their owners is really exciting.
“DWR is the perfect environment for this pioneering programme, due to the state-of-the-art equipment and depth of expertise on hand to support this life-saving initiative.”
Rob Foale, clinical director at Dick White Referrals, added: “It’s a hugely significant step for us to be launching this service, drawing on Poppy’s expertise in this field.
“We’re also starting our own blood transfusion service to complement the launch, as the pandemic has led to a huge drop in pet blood donations.
“Any excess blood we collect will be donated to the national Pet Blood Bank charity, which supplies blood to veterinary practices across the UK and does a fantastic job.”
For more information, visit www.dickwhitereferrals.com.
CardioCare is based on research carried out at the Purina Technology Center which explored how nutrients can support the ailing heart. First, a series of metabolomics studies identified metabolic changes that occur in MMVD. Then the company developed a ‘Cardiac Nutritional Blend’ to address these metabolic changes and evaluated it in a clinical study.
The main elements of the Cardiac Nutritional Blend include carnitine precursors, antioxidants and medium-chain triglycerides. Purina says the latter provides an alternative energy source that is easy for the struggling heart to use, something which is particularly important as the metabolomics research revealed that dogs with MMVD showed less efficient cardiac energy metabolism1.
The company highlights a 2019 clinical study, which showed that the Cardiac Nutritional Blend has the potential to delay disease progression in dogs with preclinical MMVD. Over the six-month study period, dogs with preclinical MMVD fed the Cardiac Nutritional Blend showed a reduction in left atrial size, while an equivalent group of dogs fed a control diet showed an increase. Additionally, none of the dogs fed the Cardiac Nutritional Blend progressed from stage B1 to B2 during the study, while 37% of dogs fed the control diet showed progression2.
Purina also says that while the research to date has focused on MMVD, the nutrients in CardioCare are recognised to be beneficial under conditions of cardiac stress and the diet may prove a useful tool to provide support in a wider range of conditions. The company recommends that the diet be considered as part of the management plan for any dog with cardiac insufficiency.
Dr Libby Sheridan, Purina Scientific Affairs Manager for the UK & Ireland, said: "Metabolomics research has the scope to drive huge advances in managing a range of conditions. We’re proud to be at the forefront of this exciting field and bring the benefits of our findings to vets in practice.
"CardioCare opens up a new avenue of support for patients with cardiac insufficiency and vets can use this diet as a tool to complement medical treatment."
CardioCare will be available from 30th June. Contact vettechline@purina.nestle.com for more information.
Chris, who is moving from Willows, will develop both the medical cardiology service and deliver a new interventional cardiology service to complement the existing surgical offering at Paragon, which is investing around £145,000 in ultrasound equipment and operating facilities to support the service.
Chris said: “I’ve had a great time at Willows and couldn’t think of a better place than Paragon to continue my passion for all things cardiology.
“It’s an exciting time to be joining Paragon, which is growing phenomenally to service the region whilst it cements itself as one of the leading referral centres in the north of England.
“The investment and expansion which is taking place at Paragon will allow us to develop another globally-recognised cardiology centre within Linnaeus.”
For more information, visit: www.paragonreferrals.co.uk
The new programme, which starts in May 2021, will address the fundamental principles underlying cardiac disease, discuss common presentations and review current diagnostic and therapeutic techniques.
Modules are delivered using a range of blended learning techniques, including interactive online lessons, supported by notes and videos.
While studying, delegates will have a module tutor – a recognised veterinary Specialist in their field - and a dedicated programme tutor, who works with individual delegates to support them through the programme.
Delegates can also choose three optional practical attendance sessions covering ECGs, thoracic radiography and echocardiography.
The programme offers a route through to achieving academic qualifications - General Practitioner Certificate (GPCert) and the Postgraduate Certificate (PgC), in partnership with the International School of Veterinary Postgraduate Studies (ISVPS) and Harper Adams University. Gaining a PgC enables delegates to apply to RCVS for Advanced Practitioner status in the subject.
Course Director Kieran Borgeat BSc BVSc MVetMed CertVC DipACVIM DipECVIM-CA MRCVS, said: "Improve International’s Cardiology DL programme features a diverse array of speakers from a variety of backgrounds, who will bring the latest information about veterinary cardiology to delegates. Our module leaders are world experts in their field so bring a thorough and uniquely engaging approach to the course material. Being able to discuss the topic with them and other course delegates online during each module of teaching during a two-year, in-depth course is a fantastic opportunity to connect with the topic as never before."
David Babington MRCVS, Business Development Director at Improve International, said: “Our cardiology programme has been designed to equip delegates with all of the skills and knowledge they need to confidently investigate, diagnose and treat cardiac patients.
“As we start to look ahead to a time beyond lockdowns, many veterinarians are taking stock and considering the next step in their career. For some, an additional qualification may be part of their plan. By offering a distance learning solution, we can ensure that, wherever in the world they are in practice, they have the opportunity to develop their clinical skills and achieve a postgraduate qualification.”
Registration information can be found here: https://www.improveinternational.com/uk/course/pgc-gpcert-small-animal-cardiology-distance-learning/
Entitled ‘Managing mitral valve disease from start to finish’, the course will account for four hours’ CPD split into six short bite-size sessions which can be completed at your own pace.
The sessions are presented by Dr Mike Martin MVB DVC MRCVS, and business thought leader, Dr Alison Lambert BVSc CMRS MRCVS. They consist of a practical review of MVD both pre-clinically and clinically and how to diagnose and stage it following the new 2019 American College of Veterinary Internal Medicine (ACVIM) Consensus guidelines.
The course also includes tips on how to treat and manage dogs with MVD with diuretic management; a step-by-step guide to treatment options for acute and long-term management of congestive heart failure and how to troubleshoot problem congestive heart failure cases.
There's also a bonus ‘Communicating Cardiology’ session which looks at how to communicate the heart disease journey to owners.
To register for the course visit www.veterinarywebinars.com/mvd-reg.
Ceva will donate £2 for every veterinary professional completing the course throughout February and March 2021 to Vetlife, which provides support to the veterinary community and their families who have emotional, health or financial concerns.